Various strategies have been developed to exploit the therapeutic potential of blocking TGF-β in tumor immunotherapy; these include antisense oligonucleotides (ASOs), neutralizing antibodies, engineered fusion proteins, and small-molecule inhibitors (119). Here, TGFB1 is linked to neoplasm.